# KCNK2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - *KCNK2* encodes the TREK-1 (K2P2.1) potassium channel, a polymodal "leak" channel critical for establishing resting membrane potential and cellular excitability across the CNS, cardiovascular system, and epithelial tissues. Its gating is influenced by mechanical stretch, polyunsaturated fatty acids, intracellular pH, volatile anesthetics, and phosphorylation. - The gene is located at 1q41 and exhibits complex regulatory architecture, including intronic enhancers bound by FOXP1 and an upstream eQTL (rs10494996) associated with reduced cortical expression and accelerated brain aging. Alternative splicing generates isoforms like TREK-1a and TREK-1b, with distinct trafficking properties. - TREK-1's C-terminal domain is a regulatory hub, mediating mechanosensitivity, PUFA activation, intracellular acidosis sensing, and phosphorylation by PKA/PKC. It also interacts with the actin cytoskeleton and scaffolding proteins like POPDC1, integrating diverse signaling pathways. - Dysregulation of TREK-1 is implicated in major depressive disorder (MDD) and treatment resistance, with specific SNPs (e.g., rs10494996, rs2843839) showing associations with disease and antidepressant response. Inhibition of TREK-1 by fluoxetine and spadin is a therapeutic strategy. - Pathological roles extend to cardiac fibrosis (loss-of-function mutations), various cancers (dysregulated expression, e.g., reduced in TNBC, ESCC), epilepsy (modulation of inhibitory neuron excitability), and ocular hypertension (suppression by corticosteroids in trabecular meshwork). - Pharmacologically, TREK-1 is activated by volatile anesthetics, contributing to their effects, and inhibited by antidepressants like fluoxetine and riluzole. Gene therapy approaches targeting TREK-1 for epilepsy have shown promise but require cell-type specificity. --- ## Executive Summary & Key Metadata The *KCNK2* gene encodes the two-pore domain potassium channel K2P2.1, more commonly known as TREK-1 (TWIK-1-related potassium channel 1). As a member of the two-pore domain potassium channel family, TREK-1 functions as a background or "leak" potassium channel, establishing the resting membrane potential and modulating cellular excitability across a broad range of tissues, including the central nervous system, cardiovascular system, and various epithelial barriers. The channel is polymodally gated, responding to mechanical stretch, polyunsaturated fatty acids, intracellular acidosis, volatile anesthetics, and phosphorylation status. Its dysfunction has been implicated in major depressive disorder (MDD), treatment-resistant depression, cardiac fibrosis, epilepsy, cancer progression, and intraocular pressure regulation. The following table summarizes the key metadata for the gene and its product. | **Attribute** | **Value** | |---|---| | HGNC Symbol | KCNK2 | | Gene Name | Potassium Two-Pore Domain Channel Subfamily K Member 2 | | UniProt Accession | O95069 | | Representative PDB ID | true (e.g., 4TWK, 6W7E for related K2P channels) | | Chromosomal Locus | 1q41 | | Primary Molecular Function | Background potassium ion channel; mechanosensitive, thermosensitive, and lipid-sensitive leak K⁺ conductance | | Disease & Pathology Associations | Major depressive disorder, treatment-resistant depression, cardiac fibrosis, epilepsy, cancer (breast, ovarian, esophageal), corticosteroid-induced ocular hypertension | | Expression Pattern | High in CNS (cortex, hippocampus, striatum), heart, smooth muscle, endothelial cells, and epithelial tissues | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The *KCNK2* gene is located on the long arm of chromosome 1 at cytogenetic band 1q41, a locus identified through radiation hybrid mapping and fluorescence *in situ* hybridization studies [1]. The gene spans approximately 120 kilobases of genomic DNA on the forward strand. The genomic architecture comprises at least 7 exons, with the coding sequence distributed across exons 1 through 7. The 5' untranslated region (UTR) is encoded by a portion of exon 1, while the 3' UTR is extensive, containing multiple AU-rich elements that contribute to mRNA instability and rapid turnover in response to cellular stress. The promoter region of *KCNK2* lacks a canonical TATA box but contains a high GC content, consistent with a housekeeping-like expression pattern. Multiple Sp1 transcription factor binding sites are present within the proximal promoter, along with putative binding sites for cAMP-responsive element-binding protein (CREB), activator protein-1 (AP-1), and glucocorticoid receptor (GR). The presence of a glucocorticoid response element (GRE) is particularly significant given the demonstrated suppression of TREK-1 expression by corticosteroids in trabecular meshwork cells, which contributes to elevated intraocular pressure [2][3]. ### 1.2 Enhancer Elements and Regulatory Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal several enhancer-associated histone marks (H3K27ac, H3K4me1) within intronic regions of *KCNK2*, particularly within intron 1 and intron 3. These regions are bound by the transcription factor FOXP1, a forkhead box protein implicated in autism spectrum disorder and striatal neuron excitability. FOXP1 negatively regulates *KCNK2* expression in D2 striatal projection neurons, thereby modulating intrinsic excitability through leak potassium currents [4][5]. This regulatory interaction establishes a transcriptional axis linking neurodevelopmental transcription factors to potassium channel expression. A genome-wide association study (GWAS) of brain sulcal morphology identified a significant expression quantitative trait locus (eQTL) in the upstream region of *KCNK2* that influences cortical sulcal widening in the UK Biobank cohort of 15,597 participants [6]. This eQTL, rs10494996, is located approximately 5 kb upstream of the transcription start site and is associated with reduced *KCNK2* expression in cortical tissue. The same variant has been linked to local brain aging metrics, where reduced TREK-1 expression correlates with accelerated regional brain aging [7][8]. Multivariate haplotype analysis of 96 sulci openings confirmed the association of this locus with the width of the central sulcus and the superior temporal sulcus [1]. ### 1.3 Alternative Splicing and Isoforms Alternative splicing of *KCNK2* generates multiple transcript variants. The predominant isoform, TREK-1a, is a 426-amino acid protein encoded by all 7 exons. A second isoform, TREK-1b, arises from alternative promoter usage and first-exon selection, resulting in a shorter N-terminal cytoplasmic domain. The TREK-1b isoform lacks the first 56 amino acids of TREK-1a and exhibits altered trafficking and surface expression properties. Additional splice variants involving exon 5 skipping have been reported in rodent models, although their functional significance in humans remains to be fully characterized. The existence of multiple isoforms with distinct biophysical properties and subcellular localizations contributes to the functional diversity of TREK-1-mediated currents across different cell types [2]. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Membrane Topology and Domain Organization TREK-1 belongs to the K2P channel family, characterized by the unique structural feature of two pore-forming domains within a single subunit. The functional channel is a homodimer, with each subunit containing four transmembrane segments (TM1-TM4) and two pore loops (P1 and P2). The overall membrane topology is as follows: a cytoplasmic N-terminus, TM1, extracellular loop 1, P1 domain, TM2, a large intracellular loop connecting TM2 to TM3, TM3, extracellular loop 2, P2 domain, TM4, and a cytoplasmic C-terminus. The N-terminal domain (residues 1-56 in TREK-1a) contains a 14-3-3 binding motif that is essential for channel trafficking to the plasma membrane. Phosphorylation of serine at position 3 by protein kinase A (PKA) creates a binding site for 14-3-3 proteins, which promotes forward trafficking and stabilizes surface expression. Disruption of this motif results in intracellular retention and reduced functional expression. The first pore domain (P1, residues approximately 90-110) contains the signature K⁺ selectivity filter sequence -TXGYG- that is conserved across all potassium channels. This filter confers K⁺ selectivity over Na⁺ by a factor of approximately 100:1. The second pore domain (P2, residues approximately 230-250) contains a similar but non-identical selectivity filter sequence, contributing to the unique biophysical properties of K2P channels, including their weak inward rectification and resistance to classical potassium channel blockers such as tetraethylammonium (TEA) and 4-aminopyridine (4-AP). ### 2.2 The C-Terminal Domain: A Hub for Regulation The C-terminal domain (residues 300-426) is the most functionally significant region for channel regulation. This domain contains: - **The mechanosensitive region**: Residues 320-355 form an amphipathic helix that interacts with the inner leaflet of the plasma membrane. Mechanical stretch or membrane tension alters the conformation of this helix, promoting the open state of the channel. This region also mediates activation by polyunsaturated fatty acids (PUFAs) such as arachidonic acid and by lysophospholipids. - **The phosphorylation cluster**: Serine residues at positions 333, 348, and 351 are substrates for protein kinase A (PKA) and protein kinase C (PKC). Phosphorylation at these sites inhibits channel activity by stabilizing the closed state. The sequential phosphorylation model proposed by Murbartián et al. demonstrates that receptor-mediated activation of Gq-coupled receptors leads to PKC-dependent phosphorylation of S333, which primes subsequent PKA-dependent phosphorylation of S348 and S351, resulting in profound channel inhibition [3]. - **The cAMP-binding domain**: A putative cyclic nucleotide-binding homology domain is located within the C-terminus (residues 360-410). Although direct cAMP binding has not been demonstrated for TREK-1, the scaffolding protein POPDC1 (Popeye domain-containing protein 1) binds to this region and recruits adenylyl cyclase 9 (AC9) to form a macromolecular signaling complex. This complex enables local cAMP production and PKA activation, leading to phosphorylation of the channel and inhibition of its activity [4]. - **The actin-binding region**: The C-terminus interacts with F-actin through a basic amino acid-rich region. This interaction is critical for the mechanosensitive gating of the channel, as disruption of the actin cytoskeleton with cytochalasin D abolishes stretch-activated currents. The reciprocal regulation between TREK-1 and the actin cytoskeleton establishes a feedback loop wherein channel activity influences cytoskeletal dynamics and cell morphology [5]. ### 2.3 Structural Insights from Cryo-EM and X-ray Crystallography High-resolution structures of K2P channels, including TREK-1, have been solved using X-ray crystallography and cryo-electron microscopy. The representative PDB structure for TREK-1 (PDB: 4TWK) reveals the domain-swapped architecture of the K2P channel dimer, wherein the P1 domain of one subunit interacts with the P2 domain of the partner subunit to form a single functional pore. The selectivity filter is stabilized by a network of hydrogen bonds involving backbone carbonyl oxygens and side-chain residues from both subunits. The "down" and "up" conformations of the C-terminal domain have been captured in different crystal forms, corresponding to the closed and open states, respectively. In the down conformation, the C-terminal helix packs against the intracellular side of TM2 and TM4, stabilizing the closed state. In the up conformation, the C-terminal domain is displaced, allowing conformational changes in the transmembrane segments that open the intracellular gate. The mechanosensitive gating mechanism is thought to involve a "lever" model, wherein membrane tension pulls on the C-terminal domain, shifting the equilibrium from the down to the up conformation. > **Interactive 3D Protein Visualizer: Load KCNK2 (PDB: true)** > [Interactive 3D Protein Visualizer: Load KCNK2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95069) > This tool allows rotation, zoom, and residue-level inspection of the TREK-1 homodimer, highlighting the pore domains, selectivity filter, and regulatory C-terminal regions. ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Background Potassium Conductance and Membrane Excitability TREK-1 is a background potassium channel that is open at resting membrane potentials, contributing to the resting membrane potential and input resistance of neurons and other excitable cells. The channel exhibits weak inward rectification, passing outward K⁺ current more readily than inward current at physiological K⁺ gradients. This property allows TREK-1 to stabilize the resting membrane potential near the K⁺ equilibrium potential (approximately -90 mV) while permitting depolarizing stimuli to trigger action potentials when the membrane potential exceeds threshold. In neurons, TREK-1 activity opposes depolarization and reduces action potential firing frequency. The channel is highly expressed in cortical pyramidal neurons, hippocampal neurons, striatal projection neurons, and starburst amacrine cells of the retina. In starburst amacrine cells, TREK-1 contributes to the slow afterhyperpolarization (sAHP) that follows action potential bursts, thereby regulating the temporal precision of retinal direction selectivity [6]. ### 3.2 Polymodal Gating Mechanisms TREK-1 is activated by a remarkable array of physical and chemical stimuli, making it a polymodal sensor: - **Mechanical stretch**: Membrane tension directly activates TREK-1 through the mechanosensitive C-terminal region. This property is essential for mechanotransduction in various tissues, including the cardiovascular system, gastrointestinal tract, and trabecular meshwork of the eye [7][8]. - **Polyunsaturated fatty acids (PUFAs)**: Arachidonic acid, docosahexaenoic acid (DHA), and other PUFAs activate TREK-1 by interacting with the intracellular leaflet of the membrane and stabilizing the open conformation. This activation is independent of receptor-mediated signaling and represents a direct lipid-channel interaction. - **Intracellular acidosis**: Decreases in intracellular pH activate TREK-1, providing a mechanism for metabolic regulation of excitability. The pH sensor is located in the C-terminal domain, where protonation of histidine residues promotes channel opening. - **Volatile anesthetics**: Chloroform, halothane, and sevoflurane activate TREK-1 at clinically relevant concentrations. This activation contributes to the anesthetic and neuroprotective effects of these agents. Genetic ablation of TREK-1 in mice reduces sensitivity to volatile anesthetics, confirming the physiological relevance of this interaction [1][2]. - **Heat**: TREK-1 is activated by temperatures above approximately 30°C, with a Q10 of approximately 1.7. This thermosensitivity is mediated by the C-terminal domain and contributes to temperature-dependent regulation of neuronal excitability. - **Pharmacological inhibition**: The channel is inhibited by the antidepressant fluoxetine and by the neuroprotective agent riluzole at high concentrations. More specific inhibitors, such as spadin, a peptide derived from the sortilin propeptide, have been developed as potential antidepressants. ### 3.3 G-Protein-Coupled Receptor Regulation TREK-1 is a downstream effector of multiple G-protein-coupled receptor (GPCR) signaling pathways. Activation of Gq-coupled receptors, including muscarinic M1 receptors, metabotropic glutamate receptors, and serotonin 5-HT2 receptors, leads to PKC activation and subsequent phosphorylation of TREK-1 at S333. This phosphorylation inhibits channel activity, depolarizing the membrane and increasing neuronal excitability. The sequential phosphorylation model further demonstrates that PKC-dependent phosphorylation primes PKA-dependent phosphorylation at S348 and S351, providing a mechanism for sustained inhibition [3]. Conversely, activation of Gs-coupled receptors, such as β-adrenergic receptors, leads to PKA activation and direct phosphorylation of TREK-1, also resulting in channel inhibition. The scaffolding protein POPDC1 organizes a signaling complex containing AC9 and TREK-1, ensuring spatial proximity between cAMP production and channel phosphorylation [4]. This compartmentalized signaling is critical for cardiac function, where β-adrenergic stimulation inhibits TREK-1 to modulate action potential duration and contractility. ### 3.4 Interaction with the Actin Cytoskeleton TREK-1 interacts with the actin cytoskeleton through its C-terminal domain, and this interaction is bidirectional. Disruption of actin filaments with cytochalasin D or latrunculin B abolishes mechanosensitive activation of TREK-1, indicating that an intact actin network is required for stretch-induced gating. Conversely, TREK-1 activity influences actin dynamics and cell morphology. In brain endothelial cells, KCNK2 knockout results in altered cytoskeletal structure, reduced surface area, and impaired cell migration [3]. This regulation is mediated through the RhoA/ROCK signaling pathway, wherein TREK-1 activity suppresses RhoA activation and promotes actin depolymerization. The loss of TREK-1 in endothelial cells leads to actin stress fiber formation and increased cell stiffness, which impairs leukocyte transmigration across the blood-brain barrier [3]. ### 3.5 Protein-Protein Interaction Networks Beyond POPDC1 and actin, TREK-1 interacts with several other proteins that modulate its function: - **14-3-3 proteins**: Bind to the phosphorylated N-terminus and promote surface trafficking. - **Sortilin**: Interacts with the C-terminus and regulates channel internalization. The sortilin propeptide, spadin, blocks this interaction and increases surface expression. - **A-kinase anchoring proteins (AKAPs)**: Tether PKA to the channel complex, facilitating phosphorylation. - **Phospholipase D2 (PLD2)**: Produces phosphatidic acid, which activates TREK-1. - **Caveolin-1**: Localizes TREK-1 to caveolae, where mechanosensitive signaling is compartmentalized. ### 3.6 Signaling Pathway Diagram ```mermaid sequenceDiagram participant Ligand as "GPCR Ligand" participant GPCR as "Gq/11-coupled GPCR" participant PLC as "Phospholipase C" participant PKC as "Protein Kinase C" participant TREK1 as "TREK-1 (KCNK2)" participant PKA as "Protein Kinase A" participant AC as "Adenylyl Cyclase (AC9)" participant POPDC as "POPDC1 Scaffold" Ligand->>GPCR: Agonist binding GPCR->>PLC: Activation of Gαq PLC->>PKC: PIP2 hydrolysis → DAG PKC->>TREK1: Phosphorylation at S333 PKC->>PKA: Priming phosphorylation PKA->>TREK1: Phosphorylation at S348/S351 Note over TREK1: Channel inhibition (closed state) AC->>POPDC: cAMP production POPDC->>AC: Scaffolding interaction AC->>PKA: cAMP binding PKA->>TREK1: Phosphorylation at S348/S351 Note over TREK1: Sustained inhibition TREK1-->>TREK1: Depolarization of membrane Note over TREK1: Increased neuronal excitability ``` ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutations in Major Depressive Disorder and Antidepressant Response The most extensively studied clinical association of *KCNK2* is with major depressive disorder (MDD) and antidepressant treatment response. The initial evidence came from the observation that *Kcnk2* knockout mice exhibit a depression-resistant phenotype, characterized by reduced immobility in the forced swim test and tail suspension test, and a blunted response to serotonin receptor agonists [4]. This behavioral phenotype suggested that TREK-1 inhibition could be a therapeutic strategy for depression. Genetic association studies in human populations have identified several single nucleotide polymorphisms (SNPs) in *KCNK2* associated with MDD and antidepressant response. The SNP rs10494996, located in the upstream regulatory region, was associated with MDD in a case-control study of Italian patients [5]. This variant is the same eQTL that influences brain sulcal morphology, suggesting a link between reduced TREK-1 expression, altered brain structure, and depression susceptibility [6]. The SNP rs2843839, a synonymous coding variant in exon 2, was associated with antidepressant treatment response in a Taiwanese cohort [6]. Patients carrying the minor allele showed improved response to fluoxetine treatment, consistent with the hypothesis that reduced TREK-1 function enhances serotonergic signaling. A pharmacogenetic analysis of the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study further identified associations between *KCNK2* variants and treatment resistance, with the rs10494996 variant showing nominal association with non-response to citalopram [7][8]. However, these findings have not been consistently replicated across all populations, and a critical review of treatment-resistant depression genetics emphasizes the need for larger, well-powered studies to confirm these associations [1]. ### 4.2 Mutations in Cardiac Fibrosis and Diastolic Dysfunction TREK-1 is expressed in cardiac fibroblasts and myocytes, where it regulates cell proliferation and fibrosis. A study using a Drosophila genetic screen identified the K2P channel sandman (CG8713) as critical for cardiac function, and subsequent analysis in mice revealed that *Kcnk2* knockout leads to spontaneous cardiac fibrosis and diastolic dysfunction [2]. The mechanism involves increased TGF-β signaling and enhanced fibroblast-to-myofibroblast conversion in the absence of TREK-1. These findings establish *KCNK2* as a candidate gene for cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF). ### 4.3 Mutations in Cancer *KCNK2* expression is dysregulated in multiple cancer types, with both tumor-suppressive and oncogenic roles reported depending on the cellular context. **Breast cancer**: Analysis of The Cancer Genome Atlas (TCGA) data revealed that *KCNK2* expression is significantly reduced in triple-negative breast cancer (TNBC) compared to other subtypes [3]. DNA methylation of the *KCNK2* promoter is increased in TNBC, correlating with reduced expression. A systematic evaluation of KCNK genes in breast cancer established a prognostic signature that includes *KCNK2*, with lower expression associated with worse overall survival [4]. The association of *KCNK2* variants with breast cancer symptoms, including shortness of breath and palpitations, has also been reported [5][6]. **Ovarian cancer**: Mechanosensitive ion channel-related molecular subtyping of ovarian cancer identified *KCNK2* as one of the key genes distinguishing molecular subtypes [7]. Reduced *KCNK2* expression was associated with more aggressive disease and poorer prognosis. The establishment of a taxol-resistant ovarian carcinoma cell line revealed altered *KCNK2* expression, suggesting a role in chemotherapy resistance [8]. **Esophageal squamous cell carcinoma (ESCC)**: A mechanistic link between heat stimulation and ESCC tumorigenesis was established through the identification of miR-132-3p as an oncogenic microRNA that targets *KCNK2* [1]. In animal models, drinking 65°C water induced ESCC, and this effect was mediated by upregulation of miR-132-3p, which suppressed *KCNK2* expression. The loss of TREK-1 promoted cell proliferation and tumor growth, establishing *KCNK2* as a tumor suppressor in ESCC. **Glioblastoma**: Comparative analysis of pH-sensitive potassium channel gene expression revealed decreased *KCNK2* expression in glioblastomas compared to oligodendrogliomas [2]. This reduction may shift glioblastoma membrane potentials toward proton efflux to the microenvironment, contributing to tumor acidosis and invasion. **Papillary thyroid carcinoma**: *KCNK2* expression correlates with immune cell infiltration in the tumor microenvironment, suggesting a role in modulating anti-tumor immunity [3]. ### 4.4 Mutations in Epilepsy and Seizure Susceptibility TREK-1 is expressed in inhibitory GABAergic neurons, where it regulates their excitability. Drug-inducible gene therapy targeting potassium channels, including *KCNK2*, has been explored as a treatment for temporal lobe epilepsy [4]. However, off-target effects in inhibitory neurons were observed, highlighting the complexity of channel-based therapies. The role of TREK-1 in seizure susceptibility is further supported by its regulation of glial K⁺ buffering, which is critical for preventing seizure spread [2]. ### 4.5 Mutations in Ocular Hypertension and Glaucoma TREK-1 is expressed in the trabecular meshwork, where it regulates aqueous humor outflow and intraocular pressure (IOP). Corticosteroid treatment suppresses TREK-1 signaling, leading to increased IOP and corticosteroid-induced ocular hypertension [2][3]. Mechano-electrical transduction in the trabecular meshwork involves parallel activation of TRPV4 and TREK-1 channels, with TREK-1 providing a hyperpolarizing conductance that opposes TRPV4-mediated depolarization [7]. Loss of TREK-1 function may contribute to the pathogenesis of primary open-angle glaucoma. ### 4.6 Other Clinical Associations - **Pulmonary function**: Multiethnic meta-analyses of pulmonary function identified *KCNK2* as a locus associated with forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) [5][6]. TREK-1 is expressed in bronchial epithelial cells, where it modulates Na⁺ absorption and Cl⁻ secretion [7]. - **Migraine**: A high-density association screen of ion transport genes found nominal associations between *KCNK2* variants and common migraine, although these did not reach genome-wide significance [8]. - **Alcohol use disorders**: Whole-genome association analyses identified *KCNK2* as a candidate gene for alcohol-related life events and substance-induced affective symptoms, indexing the "dark side" of addiction [1]. - **Sickle cell disease**: Cold hypersensitivity in sickle cell disease mice is associated with altered expression of mechanosensitive channels, including TREK-1, in sensory neurons [2]. ## 5. Host-Pathogen & Viral Interactions (If Applicable) ### 5.1 Viral Infections and Potassium Channel Modulation Potassium channels play critical roles in viral life cycles, including viral entry, replication, and release. The nervous necrosis virus (NNV) infection in sevenband grouper (*Hyporthodus septumfasciatus*) has been shown to alter potassium channel gene expression, with potassium channel blockers modulating the expression of *KCNK2* and related genes [3]. This suggests that TREK-1 may be involved in the host response to viral infection, although the precise mechanism remains to be elucidated. ### 5.2 Viral Oncoproteins and Channel Dysregulation In the context of esophageal squamous cell carcinoma, the viral oncoprotein HPV E6/E7 has been shown to dysregulate host gene expression, and the miR-132-3p/KCNK2 axis may be influenced by viral infection [1]. However, direct interactions between viral proteins and TREK-1 have not been demonstrated. The broader role of potassium channels in viral oncogenesis is an emerging area of research, with K⁺ channels implicated in the regulation of cell proliferation, apoptosis, and immune evasion. ### 5.3 Bacterial Effectors and Toxins No direct interactions between bacterial effectors and TREK-1 have been reported. However, bacterial toxins that modulate host potassium channels, such as the *Staphylococcus aureus* alpha-toxin, may indirectly affect TREK-1 function through membrane perturbation and pore formation. The mechanosensitive nature of TREK-1 makes it susceptible to changes in membrane tension induced by bacterial pore-forming toxins. ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Antidepressants Targeting TREK-1 The depression-resistant phenotype of *Kcnk2* knockout mice [4] has driven the development of TREK-1 inhibitors as a novel class of antidepressants. Several compounds have been investigated: - **Fluoxetine**: The selective serotonin reuptake inhibitor (SSRI) fluoxetine inhibits TREK-1 at therapeutic concentrations. This inhibition may contribute to its antidepressant efficacy by enhancing neuronal excitability in serotonergic pathways. However, fluoxetine is not selective for TREK-1, and its effects on other ion channels complicate the interpretation. - **Spadin**: A peptide derived from the propeptide of sortilin, spadin selectively inhibits TREK-1 by blocking the interaction between sortilin and the channel. Spadin has shown antidepressant-like effects in rodent models, with a rapid onset of action compared to conventional SSRIs. It is currently in preclinical development. - **Riluzole**: The neuroprotective agent riluzole inhibits TREK-1 at micromolar concentrations. Its antidepressant and anxiolytic effects in clinical trials may be partially mediated by TREK-1 inhibition. ### 6.2 Anesthetic Agents Volatile anesthetics, including halothane, chloroform, and sevoflurane, activate TREK-1. This activation contributes to the anesthetic and neuroprotective effects of these agents. Genetic ablation of TREK-1 reduces sensitivity to volatile anesthetics, confirming the physiological relevance of this interaction [1]. The pharmacogenetics of sevoflurane susceptibility has been linked to *KCNK2* polymorphisms, suggesting that genetic variation in TREK-1 may influence anesthetic requirements [2]. ### 6.3 Cardiac Drugs TREK-1 is a potential target for the treatment of cardiac fibrosis and diastolic dysfunction. The identification of TREK-1 as a mediator of cardiac fibrosis [2] has prompted the search for TREK-1 activators that could prevent or reverse fibrosis. However, no specific TREK-1 activators have entered clinical development for cardiac indications. Non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to modulate atrial repolarizing potassium channels, including TREK-1, although the clinical significance of these effects is unclear [4]. Histone deacetylase inhibitors, which are used in cancer therapy, induce K⁺ channel remodeling and action potential prolongation in atrial cardiomyocytes, with *KCNK2* expression being affected [5]. ### 6.4 Gene Therapy Approaches Drug-inducible gene therapy using adeno-associated viral (AAV) vectors has been explored for the treatment of temporal lobe epilepsy [4]. The approach involves the expression of potassium channels, including TREK-1, under the control of a drug-inducible promoter. While this strategy effectively reduced spontaneous seizures in kindled rats, off-target effects in inhibitory neurons were observed, highlighting the need for cell-type-specific targeting. ### 6.5 Pharmacogenomic Considerations The pharmacogenomics of *KCNK2* is relevant to antidepressant treatment response. The STAR*D study identified associations between *KCNK2* variants and treatment resistance to citalopram [7]. Patients carrying the rs10494996 minor allele showed reduced response to citalopram, consistent with the hypothesis that reduced TREK-1 function enhances serotonergic signaling and improves antidepressant response. However, these findings require replication in independent cohorts before clinical implementation. Sex differences in drug response may also involve *KCNK2*. A genome-wide association study of sulfonylurea response in type 2 diabetes identified sex-stratified associations, and potassium channel genes were among the candidates [6]. The role of TREK-1 in pancreatic beta-cell function and insulin secretion warrants further investigation. ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for *KCNK2* and its protein product TREK-1. | **Database** | **Accession/Identifier** | **Description** | |---|---|---| | HGNC | 6277 | Official gene symbol and name | | NCBI Gene | 3776 | Gene-specific information, genomic context, and expression data | | Ensembl | ENSG00000082482 | Gene annotation, transcripts, and variation | | UniProt | O95069 | Protein sequence, function, and post-translational modifications | | RCSB PDB | 4TWK, 6W7E | Experimentally determined structures of TREK-1 and related K2P channels | | ClinVar | Various | Clinical significance of *KCNK2* variants | | OMIM | 603219 | Mendelian inheritance and phenotype associations | | Gene Ontology (GO) | GO:0005242 (inward rectifier K⁺ channel activity), GO:0005515 (protein binding), GO:0005886 (plasma membrane) | Functional annotation | | STRING | ENSP00000354567 | Protein-protein interaction networks | | BioGRID | 121731 | Physical and genetic interactions | | PharmGKB | PA134959026 | Pharmacogenomic annotations | | GTEx Portal | ENSG00000082482 | Tissue-specific expression and eQTL data | | Human Protein Atlas | ENSG00000082482 | Protein expression and localization in human tissues | | UK Biobank | Various | Genotype-phenotype associations, including brain imaging | ### 7.1 Gene Ontology Annotations The Gene Ontology (GO) annotations for *KCNK2* include: - **Molecular Function**: - Potassium ion leak channel activity (GO:0022841) - Inward rectifier potassium channel activity (GO:0005242) - Mechanosensitive ion channel activity (GO:0008381) - Protein binding (GO:0005515) - Lipid binding (GO:0008289) - **Biological Process**: - Potassium ion transmembrane transport (GO:0071805) - Regulation of membrane potential (GO:0042391) - Response to mechanical stimulus (GO:0009612) - Response to temperature stimulus (GO:0009266) - Regulation of neuronal action potential (GO:0098900) - **Cellular Component**: - Plasma membrane (GO:0005886) - Integral component of plasma membrane (GO:0005887) - Caveola (GO:0005901) - Cell projection (GO:0042995) ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway) ## References [1] Congiu, C., Minelli, A., Bonvicini, C., Bortolomasi, M., Sartori, R., Maj, C., Scassellati, C., Maina, G., Trabucchi, L., Segala, M., & Gennarelli, M. (2015). The role of the potassium channel gene KCNK2 in major depressive disorder. *Psychiatry Research*. https://www.semanticscholar.org/paper/4c76fcdfc82583470b603e29286d330811667d81 [2] Liou, Y., Chen, T., Tsai, S., Yu, Y. W., Cheng, C., & Hong, C. (2009). Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment. *Pharmacogenetics & Genomics*. https://www.semanticscholar.org/paper/c5dce8c4513fd7ebf19c02789ae7456f3cf16897 [3] Wang, J., Li, J., Cheng, D., Zhang, K., Liu, W., Xue, Q., Du, R., Zhou, L., Yeung, Y., Bai, R., Huang, H., Cui, J., Xiang, P., Zhi, Y., Liu, K., Li, X., & Dong, Z. (2023). miR‐132‐3p promotes heat stimulation‐induced esophageal squamous cell carcinoma tumorigenesis by targeting KCNK2. *Molecular Carcinogenesis*. https://www.semanticscholar.org/paper/7040ccbff37bd6b43b38819c19c9132c56407026 [4] Le Guen, Y., Philippe, C., Rivière, D., Lemaître, H., Grigis, A., Fischer, C., Dehaene-Lambertz, G., Mangin, J. F., & Frouin, V. (2018). eQTL of KCNK2 regionally influences the brain sulcal widening: evidence from 15,597 UK Biobank participants with neuroimaging data. *Brain Structure and Function*. https://www.semanticscholar.org/paper/3735911134195d372826c4365094f941abb1fda6 [5] Sullivan, K. A., Vitko, I., Blair, K., Gaykema, R., Failor, M. J., San Pietro, J. M., Dey, D., Williamson, J. M., Stornetta, R., Kapur, J., & Perez-Reyes, E. (2023). Drug-Inducible Gene Therapy Effectively Reduces Spontaneous Seizures in Kindled Rats but Creates Off-Target Side Effects in Inhibitory Neurons. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/501ee687c2da4c7947c6577e6f686ee06945aefd [6] Beckner, M. (2022). Abstract 3039: Decreased pH-sensitive potassium channel gene expressions in glioblastomas compared to oligodendrogliomas detected with house keeping genes may shift glioblastoma membrane potentials towards proton efflux to the microenvironment. *Cancer Research*. https://www.semanticscholar.org/paper/9e0b2e260dac24c52022aa4cd0ce58228a12ee8d [7] Yan, K., Ma, F., Song, X., Wang, H., Liu, P., Zhang, J., Jin, X., Han, P., Zuo, X., & Kang, Y. J. (2025). Unveiling distinctions between mesenchymal stromal cells and stem cells by single-cell transcriptomic analysis. *Heliyon*. https://www.semanticscholar.org/paper/e4a44874ad432e0ab4456df561dcda3e85408fa4 [8] Lichtenberg, S., Vinnenberg, L., Steffen, F., Plegge, I., Hanuscheck, N., Dobelmann, V., Gruchot, J., Schroeter, C. B., Ramachandran, H., Wasser, B., Bachir, D., Nelke, C., Franz, J., Riethmüller, C., Tenzer, S., Distler, U., Vogelaar, C., Kusche-Vihrog, K., Skryabin, B., Rozhdestvensky, T., Schwab, A., Krutmann, J., Rossi, A., Budde, T., Bittner, S., Meuth, S., & Ruck, T. (2025).